Pediatric Nephrology

, Volume 25, Issue 3, pp 385–394 | Cite as

Phosphate binders in CKD: chalking out the differences

Review

Abstract

Plasma phosphate levels are important in the evolution of hyperparathyroidism and ectopic calcification in chronic kidney disease (CKD). Although dietary management may be adequate to control plasma phosphate in its early stages, most patients develop hyperphosphataemia by CKD stages 3−4 and require the addition of a phosphate binder. Calcium-containing phosphate binders are the most used and cheapest binders but have fallen out of favour because of the potential for positive calcium balance and calcium toxicity. This problem may be attenuated by newer phosphate binders such as sevelamer hydrochloride and lanthanum carbonate. In this review, the role of phosphate as a uraemic toxin and the advantages and disadvantages of the currently available phosphate binders are discussed.

Keywords

Children Phosphate Calcium Phosphate binders Calcium carbonate Calcium acetate Sevelamer Lanthanum 

References

  1. 1.
    Block GA, Hulbert-Shearon TE, Levin NW, Port FK (1998) Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31:607–617CrossRefPubMedGoogle Scholar
  2. 2.
    Prié D, Ureña Torres P, Friedlander G (2009) Latest findings in phosphate homeostasis. Kidney Int 75:882–889CrossRefPubMedGoogle Scholar
  3. 3.
    Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359:584–592CrossRefPubMedGoogle Scholar
  4. 4.
    Voormolen N, Noordzij M, Grootendorst DC, Beetz I, Sijpkens YW, van Manen JG, Boeschoten EW, Huisman RM, Krediet RT, Dekker FW, PREPARE study group (2007) High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant 22:2909–2916CrossRefPubMedGoogle Scholar
  5. 5.
    Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL (2005) Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16:520–528CrossRefPubMedGoogle Scholar
  6. 6.
    Goldsmith D, Ritz E, Covic A (2004) Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease? Kidney Int 66:1315–1333CrossRefPubMedGoogle Scholar
  7. 7.
    Adeney KL, Siscovick DS, Ix JH, Seliger SL, Shlipak MG, Jenny NS, Kestenbaum BR (2009) Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol 20:381–387CrossRefPubMedGoogle Scholar
  8. 8.
    Shroff RC, McNair R, Figg N, Skepper JN, Schurgers L, Gupta A, Hiorns M, Donald AE, Deanfield J, Rees L, Shanahan CM (2008) Dialysis triggers VSMC apoptosis, osteo/chodrocytic differentiation and vesicle release to cause accelerated calcification in intact human vessels. Circulation 118:1748–1757CrossRefPubMedGoogle Scholar
  9. 9.
    Shroff RC, Shah V, Hiorns MP, Schoppet M, Hofbauer LC, Hawa G, Schurgers LJ, Singhal A, Merryweather I, Brogan P, Shanahan C, Deanfield J, Rees L (2008) The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol Dial Transplant 23:3263–3271CrossRefPubMedGoogle Scholar
  10. 10.
    Bellasi A, Kooienga L, Block GA, Veledar E, Spiegel DM, Raggi P (2009) How long is the warranty period for nil or low coronary artery calcium in patients new to hemodialysis? J Nephrol 22:255–262PubMedGoogle Scholar
  11. 11.
    Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, Jahnen-Dechent W, Weissberg PL, Shanahan CM (2004) Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 15:2857–2867CrossRefPubMedGoogle Scholar
  12. 12.
    Shroff R, McNair R, Figg N, Skeper J, Deanfield J, Rees L, Shanahan C (2008) Arteries from Paediatric Dialysis Patients Show an Increased Susceptibility to Mineral Ion Induced Apoptosis and Oxidative Stress Leading to Accelerated Vesicle-Mediated Calcification. J Am Soc Nephrol 19:519ACrossRefGoogle Scholar
  13. 13.
    Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM (2000) Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87:E10–E17PubMedGoogle Scholar
  14. 14.
    Giachelli CM (2009) The emerging role of phosphate in vascular calcification. Kidney Int 75:890–897CrossRefPubMedGoogle Scholar
  15. 15.
    Shroff RC, Donald AE, Hiorns MP, Watson A, Feather S, Milford D, Ellins EA, Storry C, Ridout D, Deanfield J, Rees L (2007) Mineral metabolism and vascular damage in children on dialysis. J Am Soc Nephrol 18:2996–3003CrossRefPubMedGoogle Scholar
  16. 16.
    Mitsnefes MM, Kimball TR, Kartal J, Witt SA, Glascock BJ, Khoury PR, Daniels SR (2005) Cardiac and vascular adaptation in pediatric patients with chronic kidney disease: role of calcium-phosphorus metabolism. J Am Soc Nephrol 16:2796–2803CrossRefPubMedGoogle Scholar
  17. 17.
    Ziolkowska H, Brzewski M, Roszkowska-Blaim M (2008) Determinants of the intima-media thickness in children and adolescents with chronic kidney disease. Pediatr Nephrol 23:805–811CrossRefPubMedGoogle Scholar
  18. 18.
    Civilibal M, Caliskan S, Adaletli I, Oflaz H, Sever L, Candan C, Canpolat N, Kasapcopur O, Kuruoglu S, Arisoy N (2006) Coronary artery calcifications in children with end-stage renal disease. Pediatr Nephrol 21:1426–1433CrossRefPubMedGoogle Scholar
  19. 19.
    Litwin M, Wühl E, Jourdan C, Trelewicz J, Niemirska A, Fahr K, Jobs K, Grenda R, Wawer ZT, Rajszys P, Tröger J, Mehls O, Schaefer F (2005) Altered morphologic properties of large arteries in children with chronic renal failure and after renal transplantation. J Am Soc Nephrol 16:1494–1500CrossRefPubMedGoogle Scholar
  20. 20.
    Foley RN, Collins AJ, Herzog CA, Ishani A, Kalra PA (2009) Serum Phosphorus Levels Associate with Coronary Atherosclerosis in Young Adults. J Am Soc Nephrol 20:397–404CrossRefPubMedGoogle Scholar
  21. 21.
    Isakova T, Gutiérrez OM, Chang Y, Shah A, Tamez H, Smith K, Thadhani R, Wolf M (2009) Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 20:388–396CrossRefPubMedGoogle Scholar
  22. 22.
    Rees L, Shaw V (2007) Nutrition in children with CRF and on dialysis. Pediatr Nephrol 22:1689–1702CrossRefPubMedGoogle Scholar
  23. 23.
    Salusky IB (2006) A new era in phosphate binder therapy; What are the options? Kidney Int 70:S10–S15CrossRefGoogle Scholar
  24. 24.
    Wallot M, Bonzel KE, Winter A, Geörger B, Lettgen B, Bald M (1996) Calcium acetate versus calcium carbonate as oral phosphate binder in pediatric and adolescent hemodialysis patients. Pediatr Nephrol 10:625–630CrossRefPubMedGoogle Scholar
  25. 25.
    Delmez JA, Kelber J, Norword KY, Giles KS, Slatopolsky E (1996) Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study. Kidney Int 49:163–167CrossRefPubMedGoogle Scholar
  26. 26.
    Garland JS, Ross Morton A (2006) Sevelamer hydrochloride in peritoneal dialysis patients: Ca’canny but ca’ awa. Perit Dial Int 26:300–305PubMedGoogle Scholar
  27. 27.
    Mahdavi H, Kuizon BD, Gales B, Wang HJ, Elashoff RM, Salusky IB (2003) Sevelamer hydrochloride: an effective phosphate binder in dialyzed children. Pediatr Nephrol 18:1260–1264CrossRefPubMedGoogle Scholar
  28. 28.
    Pieper AK, Haffner D, Hoppe B, Dittrich K, Offner G, Bonzel KE, John U, Fründ S, Klaus G, Stübinger A, Düker G, Querfeld U (2006) A randomized crossover trial comparing sevelamer with calcium acetate in children with CKD. Am J Kidney Dis 47:625–635CrossRefPubMedGoogle Scholar
  29. 29.
    Salusky IB, Goodman WG, Sahney S, Gales B, Perilloux A, Wang HJ, Elashoff RM, Jüppner H (2005) Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. J Am Soc Nephrol 16:2501–2508CrossRefPubMedGoogle Scholar
  30. 30.
    Wesseling-Perry K, Harkins GC, Wang HJ, Sahney S, Gales B, Elashoff RM, Jüppner H, Salusky IB (2009) Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols. Pediatr Nephrol 24:1355–1361CrossRefPubMedGoogle Scholar
  31. 31.
    Hutchison AJ (2009) Oral phosphate binders. Kidney Int 75:906–914CrossRefPubMedGoogle Scholar
  32. 32.
    Chertow GM, Burke SK, Raggi P, Treat to Goal Working Group (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245–252CrossRefPubMedGoogle Scholar
  33. 33.
    Civilibal M, Caliskan S, Kurugoglu S, Candan C, Canpolat N, Sever L, Kasapcopur O, Arisoy N (2009) Progression of coronary calcification in pediatric chronic kidney disease stage 5. Pediatr Nephrol 24:555–563CrossRefPubMedGoogle Scholar
  34. 34.
    Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P (2005) Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68:1815–1824CrossRefPubMedGoogle Scholar
  35. 35.
    Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM (2007) Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 71:438–441CrossRefPubMedGoogle Scholar
  36. 36.
    Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK (2007) Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 72:1130–1137CrossRefPubMedGoogle Scholar
  37. 37.
    National Kidney Foundation (KDOQI) (2005) KDOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 46(Suppl 1):S1–S122Google Scholar
  38. 38.
    Chertow GM, Dillon M, Burke SK, Steg M, Bleyer AJ, Garrett BN, Domoto DT, Wilkes BM, Wombolt DG, Slatopolsky E (1999) A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 51:18–26PubMedGoogle Scholar
  39. 39.
    Savica V, Calò LA, Monardo P, Davis PA, Granata A, Santoro D, Savica R, Musolino R, Comelli MC, Bellinghieri G (2009) Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients. J Am Soc Nephrol 20:639–644CrossRefPubMedGoogle Scholar
  40. 40.
    Friedman EA (2006) Calcium-based phosphate binders are appropriate in chronic renal failure. Clin J Am Soc Nephrol 1:704–709CrossRefPubMedGoogle Scholar
  41. 41.
    Moe SM, Chertow GM (2006) The case against calcium-based phosphate binders. Clin J Am Soc Nephrol 1:697–703CrossRefPubMedGoogle Scholar
  42. 42.
    Milliner DS, Zinsmeister AR, Lieberman E, Landing B (1990) Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 38:931–936CrossRefPubMedGoogle Scholar
  43. 43.
    Shroff R, Egerton M, Bridel M, Shah V, Donald AE, Cole TJ, Hiorns MP, Deanfield JE, Rees L (2008) A bimodal association of vitamin D levels and vascular disease in children on dialysis. J Am Soc Nephrol 19:1239–1246CrossRefPubMedGoogle Scholar
  44. 44.
    Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478–1483Google Scholar
  45. 45.
    Shroff RC, Shanahan CM (2007) The vascular biology of calcification. Semin Dial 20:103–109CrossRefPubMedGoogle Scholar
  46. 46.
    Matkovic V, Heaney RP (1992) Calcium balance during human growth: evidence for threshold behaviour. Am J Clin Nutr 55:992–996PubMedGoogle Scholar
  47. 47.
    Abrams SA, Hicks PD, Hawthorne KM (2009) Higher serum 25-hydroxyvitamin D levels in school-age children are inconsistently associated with increased calcium absorption. J Clin Endocrinol Metab 94:2421–2427CrossRefPubMedGoogle Scholar
  48. 48.
    KDOQI Work Group (2009) KDOQI Clinical Practice Guideline for Nutrition in Children with Chronic Kidney Disease: 2008 update. Executive Summary. Am J Kidney Dis 53(3 Suppl 2):S11–104Google Scholar
  49. 49.
    Clayton BE, Jenkins P, Round JM (1980) Paediatric chemical pathology: clinical tests and references ranges. Oxford: Blackwell ScientificGoogle Scholar

Copyright information

© IPNA 2009

Authors and Affiliations

  1. 1.Department of NephrologyGreat Ormond Street Hospital for Children NHS TrustLondonUK
  2. 2.Renal OfficeGreat Ormond Street Hospital for ChildrenLondonUK

Personalised recommendations